Clinical Trial

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes

Study acronym: COAF-HF
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated November 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide. The hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-25.
Trial Details
NCT Number NCT06475105
Lead Sponsor Universitas Diponegoro
Conditions Acute Decompensated Heart Failure
Enrollment 66 participants
Start Date 2024-04-20
Primary Completion 2024-11-30 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-22